Skip to search formSkip to main contentSkip to account menu

bafetinib

Known as: Dual Bcr-Abl/Lyn Tyrosine Kinase Inhibitor INNO-406 
An orally active 2-phenylaminopyrimidine derivative with potential antineoplastic activity. INNO-406 specifically binds to and inhibits the Bcr/Abl… 
National Institutes of Health

Related topics

Related topics

8 relations
Fusion Proteins, bcr-ablInhibition of Cell ProliferationPositive Regulation of ApoptosisReceptor Tyrosine Kinase Inhibition

Narrower (2)

INNO-406NS-187

Broader (1)

Pyrimidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
BCR-ABL Point Mutations and TKI Treatment in CML Patients
Most newly diagnosed CML patients in the Chronic Phase (CP), when treated with imatinib, achieve durable responses. However, a… 
Review
2014
Review
2014
[Molecular targeted therapy in lymphoid leukemias].
Recent advances in the treatment of lymphoid leukemias have incorporated molecular targeted drugs (CD20-targeting rituximab and… 
2013
2013
Bafetinib inhibits functional responses of human eosinophils in vitro.
Review
2013
Review
2013
Principles and Current Topics Concerning Management of Tyrosine Kinase Inhibitor Therapy for Chronic Myelogenous Leukemia
Chronic myeloid leukemia (CML) is a chronic myeloproliferative disorder with leukemic cells featuring the Philadelphia (Ph1… 
2012
2012
Abstract 1801: Lyn and Fyn inhibition as a potential novel treatment for glioblastoma multiforme
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Background: Glioblastoma multiforme (GBM) is the… 
2011
2011
A Pilot Phase II Study of the Lyn Kinase Inhibitor Bafetinib in Patients with Relapsed or Refractory B Cell Chronic Lymphocytic Leukemia
Abstract 2858 Inhibition of B cell receptor signaling is an important mechanism of controlling the proliferation and survival of… 
Review
2010
Review
2010
Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia.
Bafetinib (NS-187, INNO-406) is a second-generation tyrosine kinase inhibitor in development by CytRx under license from Nippon… 
2010
2010
Preclinical evaluation of bafetinib for treatment of glioblastoma multiforme.
2082 Background: Despite the several advances in surgical and radiation techniques and the use of multiple chemotherapeutic drugs… 
2009
2009
The next generation of therapies for chronic myeloid leukemia.
Therapy with the tyrosine kinase inhibitor (TKI) represents the current standard first-line therapy for the management of… 
Review
2009
Review
2009
Standard management of patients with chronic myeloid leukemia.
The successful introduction of the tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of patients with chronic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)